Literature DB >> 29808915

Long-term survival after childhood acute lymphoblastic leukaemia: population-based trends in cure and relapse by clinical characteristics.

Lesley Smith1,2, Adam W Glaser2,3,4, Sally E Kinsey3,4, Darren C Greenwood1,2, Lucy Chilton5, Anthony V Moorman5, Richard G Feltbower1,2.   

Abstract

'Cure models' offer additional information to traditional epidemiological approaches to assess survival for cancer patients by simultaneously estimating the proportion cured and the survival of those 'uncured'. The proportion cured is a summary of long-term survival while the median survival time of the uncured provides important information on those who are not long-term survivors. Population-based trends in the cure proportion and survival of the uncured for childhood acute lymphoblastic leukaemia (ALL) by clinical prognostic risk factors were estimated using flexible parametric cure models, based on overall survival and event-free survival. Children aged 1-17 years diagnosed between 1990 and 2011 in Yorkshire, UK, were included (n = 492). The percentage cured increased from 77% (95% confidence interval 70-84%) in 1990-1997 to 89% (84-93%) in 2003-2011, while the median survival time of the uncured decreased from 3·2 years (2·2-4·1 years) to 0·7 years (0-1·5 years). Models based on event-free survival showed a similar trend. The 5-year cumulative incidence of relapse substantially decreased from 35% in 1990-97 to 9% in 2003-2011. These results show selective improvement in survival between 1990 and 2011 with a significant reduction in the risk of relapse alongside a reduced absolute duration of survival for those destined to be uncured.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  acute lymphoblastic leukaemia; cure; event-free survival; survival

Mesh:

Year:  2018        PMID: 29808915     DOI: 10.1111/bjh.15424

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial.

Authors:  Eni Musta; Nan van Geloven; Jakob Anninga; Hans Gelderblom; Marta Fiocco
Journal:  BMJ Open       Date:  2022-05-10       Impact factor: 3.006

2.  Prospective quantitative gene expression analysis of kallikrein-related peptidase KLK10 as a diagnostic biomarker for childhood acute lymphoblastic leukemia.

Authors:  Shwan Majid Ahmad; Basima Sadq Ahmed; Karzan Ghafur Khidhir; Heshu Sulaiman Rahman
Journal:  PeerJ       Date:  2022-05-31       Impact factor: 3.061

3.  Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.

Authors:  Wanhua Zhang; Pu Kuang; Ting Liu
Journal:  Ann Med       Date:  2019-02-14       Impact factor: 4.709

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.